103 related articles for article (PubMed ID: 16841332)
1. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.
Ramírez BS; Pestana ES; Hidalgo GG; García TH; Rodríguez RP; Ullrich A; Férnandez LE
Int J Cancer; 2006 Nov; 119(9):2190-9. PubMed ID: 16841332
[TBL] [Abstract][Full Text] [Related]
2. Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models.
Fuentes D; Chacón L; Casacó A; Ledón N; Fernández N; Iglesias A; Hernández DR; Sánchez B; Pérez R
Int Wound J; 2014 Feb; 11(1):98-103. PubMed ID: 22947303
[TBL] [Abstract][Full Text] [Related]
3. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Pérez Sánchez L; Morera Díaz Y; Bequet-Romero M; Ramses Hernández G; Rodríguez Y; Castro Velazco J; Puente Pérez P; Ayala Avila M; Gavilondo JV
Hum Vaccin Immunother; 2015; 11(8):2030-7. PubMed ID: 25891359
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine.
Ramírez BS; Alpízar YA; Fernández DR; Hidalgo GG; Capote AR; Rodríguez RP; Fernández LE
Vaccine; 2008 Sep; 26(38):4918-26. PubMed ID: 18672015
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the impact of manufacturing changes on the physicochemical properties and biological activity of Her1-ECD vaccine during product development.
Garcia Duardo K; Prieto Curbelo Y; Raymond Pous J; Rabasa Legón EY; Ramírez BS; Hernández KR; Castillo Vitoch A
Vaccine; 2015 Aug; 33(35):4292-9. PubMed ID: 26003492
[TBL] [Abstract][Full Text] [Related]
7. Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study.
Barro AM; Rivero AI; Goñi AL; Navarro BO; Angarica MM; Ramírez BS; Bedoya DM; Triana CG; Rodríguez AM; Parada ÁC
Vaccine; 2012 Dec; 31(1):89-95. PubMed ID: 23142132
[TBL] [Abstract][Full Text] [Related]
8. A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model.
Asadi-Ghalehni M; Rasaee MJ; RajabiBazl M; Khosravani M; Motaghinejad M; Javanmardi M; Khalili S; Modjtahedi H; Sadroddiny E
Microbiol Immunol; 2017 Dec; 61(12):531-538. PubMed ID: 29023946
[TBL] [Abstract][Full Text] [Related]
9. Humoral immunity responses against EGFR-positive tumor cells induced by xenogeneic EGFR expressed in the yeast Pichia pastoris.
Fang F; Chen P; Chen XC; Li J; Wen YJ; Wei YQ
Int J Mol Med; 2009 Feb; 23(2):181-8. PubMed ID: 19148541
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
11. HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects.
Alpízar YA; Ramírez BS; Fernández DR; Capote AR; Hidalgo GG; Rodríguez RP; Molina LE
Hum Vaccin; 2009 Mar; 5(3):158-65. PubMed ID: 19246985
[TBL] [Abstract][Full Text] [Related]
12. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
13. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.
Garrido G; Rabasa A; Garrido C; López A; Chao L; García-Lora AM; Garrido F; Fernández LE; Sánchez B
Oncogene; 2014 Jun; 33(24):3129-39. PubMed ID: 23975426
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapeutic effect of recombinant EGFR phage vaccine on tumors].
Liu D; Tang L; Zhou CC; Tan LS
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):728-32. PubMed ID: 17366781
[TBL] [Abstract][Full Text] [Related]
15. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
16. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody.
Garrido G; Rabasa A; Sánchez B; López MV; Blanco R; López A; Hernández DR; Pérez R; Fernández LE
J Immunol; 2011 Nov; 187(10):4954-66. PubMed ID: 21984704
[TBL] [Abstract][Full Text] [Related]
17. 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.
Garrido G; Sanchez B; Rodriguez HM; Lorenzano P; Alonso D; Fernandez LE
Hybrid Hybridomics; 2004 Jun; 23(3):168-75. PubMed ID: 15312307
[TBL] [Abstract][Full Text] [Related]
18. Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.
Novak H; Noy R; Oved K; Segal D; Wels WS; Reiter Y
Int J Cancer; 2007 Jan; 120(2):329-36. PubMed ID: 17066453
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study.
Asadi-Ghalehni M; Ghaemmaghami M; Klimka A; Javanmardi M; Navari M; Rasaee MJ
Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):274-9. PubMed ID: 25990849
[TBL] [Abstract][Full Text] [Related]
20. Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.
Labrada M; Pablos I; Prete F; Hevia G; Clavell M; Benvenuti F; Fernández LE
Hum Vaccin Immunother; 2014; 10(8):2312-20. PubMed ID: 25424937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
